Package Insert
Ascor L 500®
Ascorbic Acid
Injection, USP
(500 mg/mL)
Clinical Pharmacology Continued
administered, most of it escapes into the urine. When body tissues
are not saturated and plasma concentration is low, administration of
ascorbic acid results in little or no renal excretion.
A major
route of metabolism of ascorbic acid involves its conversion to
urinary oxalate, presumably through intermediate formation of its
oxidized product, dehydroascorbic acid.
Indications and Usage:
Ascor L
500 is indicated for ascorbic acid deficiency. Parenteral ascorbic
acid supplementation may be necessary in the treatment of scurvy for
patients with gastric disorders, for patients with extensive injuries,
for surgical patients and other who cannot take oral vitamins. Acute
ascorbic acid deficiency may be associated with extensive injuries and
other states of extreme stress. Vitamin C requirements are also
significantly increased in certain diseases and conditions such as
tuberculosis, hyperthyroidism, peptic ulcer, neoplastic disease,
pregnancy and lactation. |
|
Contraindications:
Contraindicated in those persons who have a known hypersensitivity to
any component of this preparation.
Precautions:
General Precautions:
Excessively rapid
intravenous administration is to be avoided. Temporary faintness or
dizziness may result.
Since
high internal pressure may develop on long storage, precautions should
be taken when withdrawing the solution from the vial.
Do not
administer unless solution is clear and container is intact. Discard
unused portion.
Laboratory tests:
Because ascorbic acid is
a strong reducing agent, it interferes with numerous laboratory tests
based on oxidation-reduction reactions. Diabetics taking more than
500 mg of ascorbic acid daily may obtain false readings of their
urinary glucose test. No exogenous ascorbic acid should be ingested
for 48 to 72 hours before amine-dependent stool occult blood tests are
conducted because false negative results may occur.
Material Data Safety Sheet for Ascor L
500®
 Return
to MPI Home Page
|
|
